Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of CT1812 in Older Healthy Volunteers
NCT05248672Phase 1Completed
- Sponsor
- Cognition Therapeutics, Inc.
- Start
- Feb 2022
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of zervimesine in Alzheimer's disease (AD) (3 arms), sponsored by Cognition Therapeutics, Inc. Primary endpoints: Pharmacokinetics (PK) in plasma at Day 15, Pharmacokinetics (PK) in Cerebrospinal Fluid (CSF) at Day 15 and 1 more. Started Feb 2022; status: completed.
02
Drugs
zervimesine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05248672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05248672.